A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy, safety, and tolerability of JNJ-27018966 in the treatment of patients with diarrhea-predominant irritable bowel syndrome,
Role: Investigator,
Furiex Pharmaceuticals,
(07/2012 - 07/2013)
Status: Completed